Author

Lisa A. Mahnke

Observed names: L Mahnke, L. Mahnke, Lisa Mahnke

Observed institutions: University of Bonn, University of Wisconsin–Madison, Johns Hopkins University, University of St Andrews, Washington University in St. Louis, Ripon College, Bristol-Myers Squibb (United States), Hôpital Saint-Antoine, EMD Serono, Inc. (United States), Nerviano Medical Sciences, Carlos III Hospital, Merck Healthcare KGaA, Darmstadt (Germany), Vertex Pharmaceuticals (United States), University of Cincinnati, Icahn School of Medicine at Mount Sinai

OpenAlex ID: A5015709306

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

2016 · Howard L Kaufman, Jeffery Russell, et al. · The Lancet Oncology · 1,235

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

2018 · Julius Strauss, Christopher R. Heery, et al. · Clinical Cancer Research · 407

Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV

2013 · Mark S. Sulkowski, Kenneth E. Sherman, et al. · Annals of Internal Medicine · 201

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma

2017 · Paul Nghiem, Howard L Kaufman, et al. · Future Oncology · 153

PDF

Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA

2017 · C Lance Cowey, Lisa Mahnke, et al. · Future Oncology · 118

PDF

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe

2017 · Jürgen C. Becker, Eva Lorenz, et al. · Oncotarget · 93

Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma

2017 · Dirk Schadendorf, Paul Nghiem, et al. · OncoImmunology · 62

PDF

Tn5: A Molecular Window on Transposition

1999 · William S. Reznikoff, Archna Bhasin, et al. · Biochemical and Biophysical Research Communications · 61

Clinical drug‐drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P‐glycoprotein

2014 · Sarah M. Robertson, Xia Luo, et al. · The Journal of Clinical Pharmacology · 57

Effect of Low-Dose Omeprazole (20 mg Daily) on the Pharmacokinetics of Multiple-Dose Atazanavir With Ritonavir in Healthy Subjects

2010 · Li Zhu, Anna Persson, et al. · The Journal of Clinical Pharmacology · 44

The Effect of Atazanavir/Ritonavir on the Pharmacokinetics of An Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Women

2010 · Jenny Zhang, Ellen Chung, et al. · Antiviral Therapy · 41

Conserved amino acids of the human immunodeficiency virus type 2 Vpx nuclear localization signal are critical for nuclear targeting of the viral preintegration complex in non-dividing cells

2005 · Michael Belshan, Lisa A. Mahnke, et al. · Virology · 41

PDF

Abstract CT079: Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update

2017 · Howard L. Kaufman, Jeffery S. Russell, et al. · Cancer Research · 24

Effects of the H 2 -Receptor Antagonist Famotidine on the Pharmacokinetics of Atazanavir-Ritonavir With or Without Tenofovir in HIV-Infected Patients

2011 · Xiaodong Wang, Marta Boffito, et al. · AIDS Patient Care and STDs · 19

BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression.

2020 · Johanna C. Bendell, Judy Sing-Zan Wang, et al. · Journal of Clinical Oncology · 16

Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma

2017 · Murtuza Bharmal, Fatoumata Fofana, et al. · Health and Quality of Life Outcomes · 16

PDF

Cytotoxic T cell recognition of an HIV-1 reverse transcriptase variant peptide incorporating the K103N drug resistance mutation.

2006 · Lisa Mahnke, David Clifford · AIDS Research and Therapy · 15

PDF

Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences

2018 · Howard L. Kaufman, Carla Dias Barbosa, et al. · Patient · 14

PDF

Analysis of HIV-2 Vpx by modeling and insertional mutagenesis

2006 · Lisa A. Mahnke, Michael Belshan, et al. · Virology · 14

PDF

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial.

2016 · Howard Kaufman, Jeffery Scott Russell, et al. · Journal of Clinical Oncology · 11

Evaluation of real world treatment outcomes in patients with metastatic merkel cell carcinoma (MCC) following second line chemotherapy

2016 · J. Becker, E. Lorenz, et al. · Annals of Oncology · 9

PDF

Aberrant SRN1 Reaction of 4-Aminophenol with α,p-Dinitrocumene: EPR Observation of Intermediates

2000 · Richard G. Scamehorn, Lisa A. Mahnke, et al. · Organic Letters · 9

Abstract LB_A12: Initial results from 2 Phase I studies of NMS-03305293, a selective PARP1 inhibitor

2023 · Marjolein Geurts, Dorothee Gramatzki, et al. · Molecular Cancer Therapeutics · 6

Exploratory biomarker analysis in avelumab-treated patients with metastatic Merkel cell carcinoma progressed after chemotherapy.

2017 · Irina Shapiro, Hans Juergen Grote, et al. · Journal of Clinical Oncology · 6

Real-World Outcomes of Patients with Metastatic Merkel Cell Carcinoma Treated with Second-Line or Later Chemotherapy in A Community Oncology Setting in The United States

2016 · CL Cowey, L Mahnke, et al. · Value in Health · 5

PDF

Works count: 53

Citation count: 2,698

H-index: 16

I10-index: 20